Click to go to DrugInjuryLaw Home

Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation

Free Case Evaluation

More Than 2600 Yaz / Yasmin / Ocella Lawsuits Have Been Filed As Of August 2010

First Trial In Federal Court MDL Litigation May Be As Soon As September 2011


UPDATE: October 2010: More Than 3700 YAZ / Yasmin / Ocella Lawsuits Filed To Date In Federal Court MDL

41% are venous thromboembolisms (VTE), including pulmonary embolisms (PE) and deep vein thrombosis (DVT); 43% are gallbladder injuries; 10% are strokes and heart attacks / myocardial infarctions (MI).

In the first part of August 2010 the official web site for the Yaz / Yasmin / Ocella federal court MDL litigation showed that there were 2621 personal injury and wrongful death lawsuits that had been filed on behalf of women, most of whom had developed one or more of the following side effects:

Blood Clots
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Cerebrovascular Accidents (CVA)
Heart Attack
Myocardial Infarction
Gallbladder Disease / Injury (cholecystitis)
Gallbladder Removal (cholecystectomy)

This August 2010 number of Yaz / Yasmin / Ocella MDL lawsuits is more than double the 1100 cases that Bayer had said previously were filed as of mid-February 2010.

Further, this August 2010 MDL lawsuit number does not include the Yaz / Yasmin / Ocella personal injury and wrongful death lawsuits that have been filed in the New Jersey state court "mass tort" consolidation (426 cases as of August 12, 2010) nor the Yaz / Yasmin / Ocella cases that have been filed in the Pennsylvania state court system.

At an August 11, 2010 Status Conference for the Yaz / Yasmin / Ocella federal court multi-district litigation (MDL) -- IN RE YASMIN AND YAZ (DROSPIRENONE) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION, MDL No. 2100 -- we learned that this litigation is progressing such that the first Yaz / Yasmin / Ocella trial in the federal court MDL could start in September 2011.

For some of the differences between the lawyers representing the women who have suffered these serious side effects from their use of Yaz, Yasmin, or Ocella -- who are known as the "plaintiffs" in these lawsuits -- and the attorneys for the responsible drug companies -- known as the "defendants" -- we provide this excerpt from the official MINUTES OF STATUS CONFERENCE:

Regarding trial scheduling... [the plaintiffs] proposed to defendants a schedule that would get things done and setting trials by next September. They agreed on general timing and how cases will be selected but from plaintiffs’ perspective, plaintiffs should be able to pick cases to present to juries. Counsel to discuss this and their goal is to have a program in place where depositions will take place and experts disclosed to shoot for early trial in September 2011. [The drug company attorney] agrees cases need to proceed but disagree in the process. They believe in Bellwether type of process where defendants should also have input on what cases are tried.... They will address this further at the next conference [which is scheduled for September 16, 2010].

Our law firm represents people in personal injury and wrongful death cases that involve a deep vein thrombosis (DVT), pulmonary embolism (PE), stroke or cerebrovascular accident (CVA), heart attack or myocardial infarction (MI), gallbladder removal (cholecystectomy), and other serious adverse reactions caused by YAZ, Yasmin, Ocella, Gianvi, Zarah, Loryna, Syeda, Beyaz, and Safyral birth control pills.

We will continue to monitor the Yaz / Yasmin / Ocella litigation -- not only the federal court MDL but also the New Jersey "mass tort" consolidation and the lawsuits that have been filed in the Pennsylvania state court system -- so that we can keep our clients informed about significant developments.

Go to Free Case Evaluation form >>

Read more on our Drospirenone (DRSP) Birth Control Pillsl Information Page >>

  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535